Molecular Biology of the Cell Call for Nominations: MBC Editor-in-Chief

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Originally published as MBC in Press, 10.1091/mbc.E07-07-0713 on December 12, 2007

Vol. 19, Issue 2, 711-721, February 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
E07-07-0713v1
19/2/711    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Balla, A.
Right arrow Articles by Balla, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Balla, A.
Right arrow Articles by Balla, T.

Maintenance of Hormone-sensitive Phosphoinositide Pools in the Plasma Membrane Requires Phosphatidylinositol 4-Kinase III{alpha}

Andras Balla*,{dagger}, Yeun Ju Kim*, Peter Varnai*,{dagger}, Zsofia Szentpetery*, Zachary Knight{ddagger}, Kevan M. Shokat§, and Tamas Balla*

*Section on Molecular Signal Transduction, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892; {dagger}Department of Physiology, Semmelweis University, School of Medicine, Budapest, Hungary H-1086; {ddagger}Program in Chemistry and Chemical Biology, University of California, San Francisco, CA 94158; and §Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA 94158

Submitted July 28, 2007; Revised October 25, 2007; Accepted November 27, 2007
Monitoring Editor: John York

Type III phosphatidylinositol (PtdIns) 4-kinases (PI4Ks) have been previously shown to support plasma membrane phosphoinositide synthesis during phospholipase C activation and Ca2+ signaling. Here, we use biochemical and imaging tools to monitor phosphoinositide changes in the plasma membrane in combination with pharmacological and genetic approaches to determine which of the type III PI4Ks ({alpha} or β) is responsible for supplying phosphoinositides during agonist-induced Ca2+ signaling. Using inhibitors that discriminate between the {alpha}- and β-isoforms of type III PI4Ks, PI4KIII{alpha} was found indispensable for the production of phosphatidylinositol 4-phosphate (PtdIns4P), phosphatidylinositol 4,5-bisphosphate [PtdIns(4,5)P2], and Ca2+ signaling in angiotensin II (AngII)-stimulated cells. Down-regulation of either the type II or type III PI4K enzymes by small interfering RNA (siRNA) had small but significant effects on basal PtdIns4P and PtdIns(4,5)P2 levels in 32P-labeled cells, but only PI4KIII{alpha} down-regulation caused a slight impairment of PtdIns4P and PtdIns(4,5)P2 resynthesis in AngII-stimulated cells. None of the PI4K siRNA treatments had a measurable effect on AngII-induced Ca2+ signaling. These results indicate that a small fraction of the cellular PI4K activity is sufficient to maintain plasma membrane phosphoinositide pools, and they demonstrate the value of the pharmacological approach in revealing the pivotal role of PI4KIII{alpha} enzyme in maintaining plasma membrane phosphoinositides.


This was published online ahead of print in MBC in Press (http://www.molbiolcell.org/cgi/doi/10.1091/mbc.E07-07-0713) on December 12, 2007.

1 Because AngII treatment increases the labeling of PtdIns/PtdA, and the knockdown of the individual enzymes could also affect this response, the correction for cell loss due to knockdown of the enzymes was based on the PtdIns/PtdA values obtained in the unstimulated cells also for the in AngII-stimulated samples. We assumed that AngII treatment does not cause cell loss.

Address correspondence to: Tamas Balla (ballat{at}mail.nih.gov)

Abbreviations used: 5-ptase, type-IV phosphoinositide 5-phosphatase; AngII, angiotensin II; DTT, dithiothreitol; ER, endoplasmic reticulum; FAPP, four phosphate adaptor protein; FRET, fluorescence resonance energy transfer; GFP, enhanced green fluorescent protein; InsP3, inositol trisphosphate; Mer, β-mercaptoethanol; mRFP, monomeric red fluorescent protein; OSBP, oxysterol binding protein; PAO, phenylarsine oxide; PI4K, phosphatidylinositol 4-kinase; PtdIns4P, phosphatidylinositol 4-phosphate; PtdIns(4,5)P2, phosphatidylinositol 4,5-bisphosphate; PtdA, phosphatidic acid; PLC, phospholipase C; PH, pleckstrin homology; siRNA, small interfering RNA; Wm, wortmannin.




This article has been cited by other articles:


Home page
JGPHome page
T.-M. Wang and D. W. Hilgemann
Ca-dependent Nonsecretory Vesicle Fusion in a Secretory Cell
J. Gen. Physiol., July 1, 2008; 132(1): 51 - 65.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
G. D'Angelo, M. Vicinanza, A. Di Campli, and M. A. De Matteis
The multiple roles of PtdIns(4)P - not just the precursor of PtdIns(4,5)P2
J. Cell Sci., June 15, 2008; 121(12): 1955 - 1963.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2008 by The American Society for Cell Biology. Terms of copyright protection, warranties, and disclaimers.